HGS has substantial financial rights to a number of products in the GSK clinical pipeline. Two of these have advanced to Phase 3 development.

Darapladib is a selective and orally active inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that has been identified in clinical trials as an independent risk factor for coronary heart disease and ischemic stroke. GSK has initiated a pivotal Phase 3 trial to evaluate the efficacy and safety of treatment with the investigational Lp-PLA2 inhibitor darapladib to reduce the risk of cardiovascular events in men and women with chronic coronary heart disease. Darapladib was discovered by GSK based on HGS technology, and it has the potential to be an important new treatment for the prevention of cardiovascular risk.

Albiglutide is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. GSK has initiated a Phase 3 clinical trial program to evaluate the safety and efficacy of albiglutide in the long-term treatment of type 2 diabetes mellitus. Albiglutide was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004.

For additional information about any of the GSK products to which HGS has rights, please contact GSK directly.